Targeted treatments of radio-iodine refractory differentiated thyroid cancer

Area of Science:

• Oncology
• Pharmacology

Background:

• Radio-iodine refractory metastatic thyroid cancer management was historically complex.
• The rarity of these cancers presented significant therapeutic challenges.

Purpose of the Study:

• To review the impact of new therapeutic agents and organizational changes in managing radio-iodine refractory metastatic thyroid cancer.
• To highlight advancements in targeted therapies and multidisciplinary care.

Main Methods:

• Review of randomized phase III trials for kinase inhibitors (sorafenib, lenvatinib).
• Assessment of interventional radiology techniques and national care network development (TUTHYREF).

Main Results:

• Sorafenib and lenvatinib demonstrated significant improvements in response rate and progression-free survival compared to placebo.
• These targeted agents received regulatory approval for radio-iodine refractory metastatic thyroid cancer.
• Development of interventional radiology and a national network (TUTHYREF) enhanced patient care.

Conclusions:

• Kinase inhibitors represent a major breakthrough in treating radio-iodine refractory metastatic thyroid cancer.
• Integrated care models, including multidisciplinary teams and specialized networks, are crucial for optimal patient management.